Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stanley, W.C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stanley, W.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy

W.C. Stanley*

Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio, U.S.A.

* Correspondence: William C. Stanley, PhD, Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4970, U.S.A..

Abstract

Cardiac work requires a high rate of adenosine triphosphate (ATP) breakdown. ATP is resynthesized in the mitochondria with energy from the combustion of fatty acids, glucose and lactate. Fatty acids are the main fuel for the heart, supplying 60–90% of the energy, with the balance (10–40%) from pyruvate oxidation (formed from glycolysis and lactate). Fatty acid oxidation inhibits pyruvate oxidation in the mitochondria. During myocardial ischaemia, oxygen consumption and ATP production is reduced, causing accelerated glycolysis and lactate production; the pH falls and cell function is impaired. Paradoxically, with a partial reduction in coronary flow, the myocardium continues to derive most of its energy from the oxidation of fatty acids despite a high rate of lactate production; this fatty acid oxidation during ischaemia inhibits pyruvate oxidation, and drives pyruvate conversion to lactate. Partial inhibition of fatty acid oxidation in ischaemic myocardium, such as with the long-chain 3-ketoacyl thiolase inhibitor trimetazidine, reduces lactate production and H+ accumulation during ischaemia, and results in clinical benefit in patients with angina pectoris.

Key Words: Angina pectoris • cardiac • coronary artery disease • fatty acids • glucose • heart • lactate • metabolism • mitochondria

References

  1. Opie L. The Heart: Physiology, from Cell to Circulation. Philadelphia: Lippincott-Raven; 1998.
  2. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243–257[Free Full Text]
  3. Balaban RS, Kantor HL, Katz LA, Briggs RW. Relation between work and phosphate metabolite in the in vivo paced mammalian heart. Science. 1986;232:1121–1123[Abstract/Free Full Text]
  4. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans: dual carbon-labeled carbohydrate isotope experiments. J Clin Invest. 1988;82:2017–2025
  5. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest. 1985;76:1819–1827
  6. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids: studies with 14C-labeled substrates in humans. J Clin Invest. 1987;79:359–366
  7. Wisneski JA, Stanley WC, Gertz EW, Neese RA. Effects of hyperglycemia on myocardial glycolytic activity in normal humans. J Clin Invest. 1990;85:1648–1656
  8. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263–276[Medline]
  9. Hansford RG, Cohen L. Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys. 1978;191:65–81[CrossRef][Web of Science][Medline]
  10. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;ii:785–789
  11. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J. 1964;93:652–665[Web of Science][Medline]
  12. Lassers BW, Wahlqvist ML, Kaijser L, Carlson LA. Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol. 1972;33:72–80[Free Full Text]
  13. Stone CK, Holden J, Stanley WC, Perlman SB. Effect of substrate availability upon cardiac glucose uptake. J Nucl Med. 1995;36:996–1002[Abstract/Free Full Text]
  14. Lopaschuk GD, Spafford M, Davies NJ, Wall SR. Glucose and palmitate oxidation in isolated working rat hearts reperfused following a period of transient global ischemia. Circ Res. 1990;66:546–553[Abstract/Free Full Text]
  15. Schwartz GG, Greyson C, Wisneski JA, Garcia J. Inhibition of fatty acid metabolism alters myocardial high-energy phosphates in vivo. Am J Physiol. 1994;267:H224–H231
  16. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588[Abstract/Free Full Text]
  17. Liedtke AJ. Alterations in carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981;23:321–326[CrossRef][Web of Science][Medline]
  18. Fabiato A, Fabiato F. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned cells from cardiac and skeletal muscles. J Physiol (Lond). 1978;276:233–255[Abstract/Free Full Text]
  19. Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68:1250–1258[Abstract/Free Full Text]
  20. McNulty PH, Sinusas AJ, Shi CQ, et al. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. J Clin Invest. 1996;98:62–69[Web of Science][Medline]
  21. Lopaschuk GD, Collins-Nakai R, Olley PM, et al. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J. 1994;128:61–67[CrossRef][Web of Science][Medline]
  22. Stanley WC, Hernandez LA, Spires DA, Bringas J, Wallace S, McCormack JG. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium: effects of dichloroacetate. J Mol Cell Cardiol. 1996;29:905–914
  23. Schoder H, Knight RJ, Kofoed KF, Schelbert HR, Buxton DB. Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochim Biophys Acta. 1998;1406:62–72[Medline]
  24. Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J. 1980;1:247–253
  25. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4:853–860
  26. McCormack JG, Stanley WC, Wolff AA. Pharmacology of ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol. 1998;30:639–645[Web of Science][Medline]
  27. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propanolol in patients with stable angina. Br J Clin Pharmacol. 1994;37:279–288[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley
Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stanley, W.C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stanley, W.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?